<DOC>
	<DOCNO>NCT01966809</DOCNO>
	<brief_summary>This study aim investigate effectiveness treatment brain tumor call Photodynamic Therapy , PDT . Briefly , subject receive light-sensitive drug , call Photofrin® , day tumor removal surgery . The next day , tumor remove , red light laser shone tumor cavity light-diffusing sphere . This light activate photosensitizer , possibly kill tumor cell may leave . We plan measure long subject may go without new tumor regrowth , overall long subject survive . We compare result typical result see see improvement . Objective : To define antitumor activity Photofrin® laser light activation within confines Phase II study .</brief_summary>
	<brief_title>Photodynamic Therapy ( PDT ) For Recurrent High Grade Gliomas</brief_title>
	<detailed_description>Photodynamic therapy ( PDT ) well-known treatment type tumor ; however experimental treatment brain tumor . There much know effectiveness PDT patient brain tumor . The purpose study define antitumor activity Photofrin® laser light activation . Photofrin® photosensitize drug ( dye activate light ) use PDT . We want test activity PDT see effect ( good bad ) brain tumor . We also want learn treatment cause brain tumor shrink whether help patient brain tumor live longer . PDT cancer treatment involve give photosensitive dye ( Photofrin® ) , vein tube ( call IV ) . This dye go inside cancer cell go inside normal , healthy cell . PDT use Photofrin® approve treatment patient certain type cancer lung , esophageal ( mouth stomach ) cancer . Everyone study receive Photofrin® ( porfimer sodium ) injection ( Pinnacle Biologics , Inc. , Bannockburn , IL , USA ) , treat red light emit red laser . The light sent laser surface brain tumor locate use light transmit fiber . The fiber knob end spread light evenly direction . Previous study show patient malignant brain tumor call gliomas good response PDT . The patient study live longer expect live . In one study adult brain tumor Australia , patient give PDT greatly improve survival rate . Fifty seven percent ( 57 % ) patient gliomas call anaplastic astrocytoma survive 36 month . Thirty seven percent ( 37 % ) patient gliomas call glioblastoma multiforme survive 36 month . Froedtert Hospital , Milwaukee WI , involve PDT study adults past . This current study do similar way study do Australia , use increase Photofrin® ) light dose previous study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Hematoporphyrin Derivative</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>Inclusion Criteria 1 . Age : Greater equal 18 year age . 2 . Disease : Patients relapse refractory high grade glioma eligible . Patients must histologic verification malignancy original diagnosis relapse . Tumors must supratentorial location . 3 . Disease Status : Patients must potentially resectable disease . 4 . Therapeutic Options : Patient 's current disease state must one know curative therapy therapy proven prolong survival acceptable quality life . 5 . Performance Level : Karnofsky 50 % great . Note : Neurologic deficit patient CNS tumor must relatively stable least 7 day prior study enrollment . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . 6 . Predictable Life Expectancy : &gt; 8weeks 7 . Prior Therapy : Patients must fully recover acute toxic effect prior anticancer chemotherapy . At least three week previous chemotherapy 4 week prior radiation therapy . 8 . Organ Function : . Adequate bone marrow function . Absolute neutrophil count ≥ 1,000 ii . Platelet count ≥ 100,000 ( may transfuse meet requirement ) b . Adequate renal function i. Creatinine clearance radioisotope GFR ≥ 60 mL/min/1.73 m2 ii . A serum creatinine within normal range base age/gender . c. Adequate liver function i. Bilirubin ( direct ) ≤ 3X upper limit normal ( ULN ) age ii . SGPT ( ALT ) ≤ 10X ULN . For purpose study , ULN SGPT 45 U/L . iii . Serum albumin ≥ 2 g/dL . d. Adequate coagulation i. PT INR ≤ 2X ULN age . 9 . Central Nervous System Function : Patients seizure disorder may enrol receive nonenzyme inducing anticonvulsant well control . 10 . Informed Consent : All patient legally authorize representative must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 11 . Archival tumor tissue slide initial diagnosis review Froedtert HealthMCW neuropathologist prior study enrollment whenever possible . Exclusion Criteria 1 . Disseminated disease 2 . Pregnancy BreastFeeding : Pregnant breastfeed woman enter study , risk fetal teratogenic adverse effect Photofrin® know . 3 . Other concurrent tumor therapy 4 . Subjects porphyria 5 . Subjects take potentially photosensitize drug ( Appendix 3 ) 6 . The presence adverse event neurologic function , photosensitivity , photophobia Grade 4 high ( CTCAE Version 4.02 ) .47 7 . Allergy egg , soybean oil , safflower oil ( due potential allergy intralipids ) 8 . Patients opinion investigator may able comply safety monitoring requirement study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Brain Tumor</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Photochemotherapy</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Pilocytic Astrocytoma</keyword>
	<keyword>Low grade Astrocytoma</keyword>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Chordoma</keyword>
	<keyword>Germinoma</keyword>
	<keyword>Germ Cell Tumor</keyword>
	<keyword>Non-germinoma</keyword>
	<keyword>CNS Lymphoma</keyword>
	<keyword>Craniopharyngioma</keyword>
	<keyword>Mixed Glioma</keyword>
	<keyword>Optic Nerve Glioma</keyword>
	<keyword>Meningioma</keyword>
	<keyword>Oligodendroglioma</keyword>
	<keyword>Pituitary Tumors</keyword>
	<keyword>Desmoplastic Neuroepithelial Tumor</keyword>
	<keyword>DNET</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>glioma</keyword>
	<keyword>glioblastoma survivor</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>gbm cancer</keyword>
	<keyword>oligoastrocytoma</keyword>
	<keyword>gbm tumor</keyword>
	<keyword>anaplastic oligodendroglioma</keyword>
	<keyword>High-Grade Glioma</keyword>
	<keyword>high grade glioma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>glioblastoma cancer</keyword>
	<keyword>anaplastic oligoastrocytoma</keyword>
	<keyword>astrocytoma glioma</keyword>
	<keyword>glioblastoma clinical trial</keyword>
	<keyword>photodynamic therapy cancer</keyword>
	<keyword>glioblastoma multiforme clinical trial</keyword>
	<keyword>astrocytoma glioblastoma</keyword>
	<keyword>gbm grade 4</keyword>
	<keyword>clinical trial glioblastoma</keyword>
	<keyword>photodynamic therapy cancer</keyword>
	<keyword>clinical trial glioblastoma</keyword>
	<keyword>glioblastoma clinical trial 2015</keyword>
	<keyword>glioblastoma clinical trial 2014 open 2014</keyword>
	<keyword>glioblastoma trial</keyword>
	<keyword>gbm clinical trial</keyword>
	<keyword>glioblastoma immunotherapy</keyword>
	<keyword>malignant glioma</keyword>
	<keyword>anaplastic astrocytomas</keyword>
	<keyword>immunotherapy glioblastoma</keyword>
	<keyword>immunotherapy glioblastoma</keyword>
	<keyword>High Grade Glioblastoma Multiforme</keyword>
	<keyword>clinical trial glioblastoma</keyword>
	<keyword>glioblastoma clinical trial</keyword>
	<keyword>glioblastoma trial</keyword>
	<keyword>brain tumor</keyword>
	<keyword>recurrent brain tumor</keyword>
	<keyword>glioma grade 3</keyword>
	<keyword>grade 3 brain tumor</keyword>
	<keyword>grade 4 brain tumor</keyword>
</DOC>